GO:0002457 T cell antigen processing and presentation: Immune Surveillance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002457 describes the process by which a T cell expresses antigen (peptide or lipid) on its surface in association with an MHC protein complex.
• This process is distinct from classical antigen presentation by professional antigen-presenting cells, though it shares core molecular machinery.
• T cell antigen processing and presentation is critical for thymic selection, peripheral T cell activation, and anti-tumor immunity.
• Defects in this pathway contribute to immune evasion in cancer and are being targeted for vaccine development.
• Key genes include MHC class I and II molecules, beta-2-microglobulin, TAP1/2, and cathepsins, among others.
• CRISPR knockout, knock-in, and overexpression models are essential for dissecting the functional roles of these genes in T cells.
Description
T cell antigen processing and presentation (GO:0002457) is a biological process in which a T cell expresses antigen, either peptide or lipid, on its cell surface in association with an MHC protein complex. This process is fundamental to adaptive immunity, enabling T cells to survey their environment, interact with other immune cells, and initiate or regulate immune responses. Unlike professional antigen-presenting cells (APCs) such as dendritic cells, T cells themselves can process and present antigens, a phenomenon that has gained increasing attention for its roles in thymic selection, peripheral tolerance, and anti-tumor immunity. Understanding this process at the molecular level is essential for researchers studying immune evasion, autoimmunity, and cancer immunotherapy. Recent advances have highlighted the importance of T cell antigen presentation in tumor immunogenicity and the development of novel vaccine strategies.
T cell antigen processing and presentation At A Glance
| GO ID | GO:0002457 |
|---|---|
| GO term | T cell antigen processing and presentation |
| Ontology | biological_process |
| Synonym | T-cell antigen processing and presentation; T lymphocyte antigen processing and presentation; T-lymphocyte antigen processing and presentation |
| Major function | Expression of antigen (peptide or lipid) on the T cell surface in association with an MHC protein complex |
| Cellular location | Plasma membrane, endosomal compartments, endoplasmic reticulum |
| Key molecules | MHC class I and II, beta-2-microglobulin, TAP1/2, tapasin, cathepsins, invariant chain (CD74) |
| Related processes | Antigen processing and presentation (GO:0019882), MHC class I presentation (GO:0002474), MHC class II presentation (GO:0002504) |
What Is GO:0002457?
According to the Gene Ontology, GO:0002457 is defined as the process in which a T cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex. This encompasses the intracellular processing of antigens, their loading onto MHC molecules, and their subsequent presentation at the plasma membrane. It is a specialized form of antigen presentation that occurs within T cells themselves, distinguishing it from antigen presentation by classical APCs.
Why Is T cell antigen processing and presentation Important in Cell Biology?
T cell antigen processing and presentation is crucial for the initiation and regulation of adaptive immune responses. It enables T cells to present antigens to other T cells or to interact with APCs, influencing thymic selection, peripheral tolerance, and effector functions. Dysregulation of this process is implicated in cancer immune evasion, where tumor cells often downregulate MHC molecules or antigen processing machinery to escape T cell recognition. Moreover, understanding this pathway is essential for designing effective cancer vaccines and immunotherapies that rely on T cell-mediated killing.
• Enables T cells to present antigens and interact with other immune cells, shaping immune responses.
• Critical for thymic selection and the establishment of central tolerance.
• Plays a role in peripheral T cell activation and effector functions.
• Dysregulation contributes to cancer immune evasion and resistance to immunotherapy.
• Targeted by novel vaccine strategies to enhance anti-tumor immunity.
• Involved in autoimmune diseases through aberrant presentation of self-antigens.
• Provides a mechanism for T cell-mediated regulation of immune responses.
• Serves as a biomarker for immune competence and disease prognosis.
• Offers therapeutic targets for modulating immune responses in cancer and autoimmunity.
• Essential for understanding the mode of action of checkpoint inhibitors and other immunotherapies.
What Happens During T cell antigen processing and presentation?
Antigen Uptake and Processing
In simple terms: T cells take in antigens and break them down into smaller pieces.
T cells can acquire antigens through various mechanisms, including phagocytosis, endocytosis, or direct transfer from other cells. Once internalized, antigens are processed in endosomal compartments where proteases such as cathepsins degrade them into peptides suitable for loading onto MHC molecules. This step is essential for generating the antigenic repertoire that will be presented on the cell surface.
MHC Class I Loading and Presentation
In simple terms: Peptides are loaded onto MHC class I molecules and sent to the cell surface.
In the classical MHC class I pathway, cytosolic peptides are transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP), where they are loaded onto MHC class I molecules with the help of the peptide-loading complex. The peptide-MHC class I complexes then travel through the Golgi to the plasma membrane for presentation to CD8+ T cells. In T cells, this pathway can present endogenous antigens as well as antigens acquired from the environment.
MHC Class II Loading and Presentation
In simple terms: Peptides are loaded onto MHC class II molecules in specialized compartments.
MHC class II molecules are synthesized in the ER and associate with the invariant chain (CD74) to prevent premature peptide binding. They are then routed to endosomal compartments where the invariant chain is degraded, and antigenic peptides derived from endocytosed material are loaded onto MHC class II. These complexes are then presented on the cell surface to CD4+ T cells. T cells can express MHC class II under certain conditions, enabling them to present antigens to CD4+ T cells.
Cross-Presentation and Lipid Antigen Presentation
In simple terms: T cells can also present antigens from outside or lipids to specialized T cells.
Cross-presentation allows antigens taken up from the extracellular environment to be presented on MHC class I molecules, a process important for immunity against tumors and viruses. Additionally, lipid antigens can be presented by CD1 molecules, which are MHC-like proteins. T cells expressing CD1 molecules can present lipid antigens to specialized T cell subsets such as NKT cells.
Regulation and Modulation of Presentation
In simple terms: The presentation process is controlled by signals that can increase or decrease it.
The efficiency of antigen processing and presentation in T cells can be modulated by various signals, including cytokines, costimulatory molecules, and metabolic cues. For example, Wnt5A signaling has been shown to support antigen processing and CD8 T cell activation. Additionally, extracellular vesicles from activated T cells can transfer DNA to enhance antigen presentation in recipient cells. These regulatory mechanisms ensure that antigen presentation is tightly controlled to avoid autoimmunity while enabling effective immune responses.
Key Genes Involved in GO:0002457 T cell antigen processing and presentation
The following genes and proteins are central to T cell antigen processing and presentation, based on their established roles in MHC biology, antigen processing, and T cell function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-A | MHC class I heavy chain; presents endogenous peptides to CD8+ T cells | Target for enhancing tumor immunogenicity; frequently downregulated in cancers |
| HLA-B | MHC class I heavy chain; presents viral and tumor peptides | Polymorphisms influence immune response and disease susceptibility |
| HLA-C | MHC class I heavy chain; presents peptides to NK and T cells | Regulates NK cell education and T cell responses |
| B2M | Beta-2-microglobulin; light chain of MHC class I | Mutations cause loss of MHC class I presentation and immune evasion |
| TAP1 | Transports peptides into ER for MHC class I loading | Defects lead to impaired antigen presentation and immunodeficiency |
| TAP2 | Transports peptides into ER for MHC class I loading | Polymorphisms affect peptide repertoire and immune response |
| TAPBP | Tapasin; bridges TAP and MHC class I, stabilizes peptide loading complex | Essential for optimal peptide loading and MHC class I stability |
| HLA-DRA | MHC class II alpha chain; presents exogenous peptides to CD4+ T cells | Expression on T cells modulates CD4+ T cell responses |
| HLA-DRB1 | MHC class II beta chain; presents peptides to CD4+ T cells | Associated with autoimmune diseases and cancer immunity |
| CD74 | Invariant chain; chaperones MHC class II and blocks peptide binding | Regulates MHC class II trafficking and antigen presentation |
| CTSB | Cathepsin B; protease involved in antigen processing | Influences peptide repertoire and T cell activation |
| CTSL | Cathepsin L; protease involved in invariant chain degradation | Critical for MHC class II peptide loading |
| CTSS | Cathepsin S; protease that degrades invariant chain | Required for MHC class II antigen presentation |
| PSMB8 | Immunoproteasome subunit; generates peptides for MHC class I | Upregulated in immune cells; affects antigen processing |
| PSMB9 | Immunoproteasome subunit; generates peptides for MHC class I | Polymorphisms linked to autoimmune and infectious diseases |
| PSMB10 | Immunoproteasome subunit; generates peptides for MHC class I | Modulates peptide repertoire presented by MHC class I |
| CD1D | Presents lipid antigens to NKT cells | Important for lipid antigen presentation and NKT cell activation |
| WNT5A | Signaling molecule that supports antigen processing | Enhances CD8 T cell activation and antigen presentation |
How Is T cell antigen processing and presentation Regulated?
The process of T cell antigen processing and presentation is regulated at multiple levels, including transcriptional control of MHC and antigen processing genes, post-translational modifications, and signaling pathways. Cytokines such as interferon-gamma upregulate MHC class I and II expression and components of the antigen processing machinery. Wnt5A signaling has been shown to support antigen processing and CD8 T cell activation. Additionally, extracellular vesicles from activated T cells can transfer DNA to enhance antigen presentation in recipient cells. These regulatory mechanisms ensure that antigen presentation is appropriately tuned to the immune context, preventing autoimmunity while enabling effective responses against pathogens and tumors.
T cell antigen processing and presentation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B2M | Cancer immune evasion; loss of MHC class I presentation | B2M knockout in tumor cell lines; syngeneic mouse models |
| TAP1 | Immunodeficiency; impaired peptide transport | TAP1 knockout mice; patient-derived cells |
| HLA-DRB1 | Autoimmune diseases (e.g., rheumatoid arthritis) | HLA-DRB1 transgenic mice; CRISPR knock-in of risk alleles |
| CTSS | Autoimmunity; defective invariant chain processing | Ctss knockout mice; T cell-specific deletion |
| WNT5A | Cancer; modulation of antigen presentation | Wnt5a knockout or overexpression in T cells; tumor models |
Cancer Immune Evasion
Tumors frequently evade immune detection by downregulating MHC class I molecules and antigen processing machinery, thereby impairing T cell antigen presentation and recognition. Defects in antigen processing and presentation are a major mechanism of immune evasion and resistance to checkpoint blockade therapies. Understanding these defects is crucial for developing strategies to restore antigen presentation and enhance anti-tumor immunity.
Autoimmunity
Aberrant T cell antigen processing and presentation can lead to the presentation of self-antigens, contributing to autoimmune diseases such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis. Polymorphisms in MHC class II genes, particularly HLA-DRB1, are strongly associated with autoimmune susceptibility. Modulating antigen presentation pathways is a potential therapeutic strategy for autoimmune disorders.
Immunodeficiencies
Mutations in genes involved in antigen processing and presentation, such as TAP1, TAP2, and B2M, can cause primary immunodeficiencies characterized by impaired T cell responses and increased susceptibility to infections. These rare disorders highlight the non-redundant roles of these genes in human immunity.
Infectious Diseases
Pathogens have evolved mechanisms to interfere with antigen processing and presentation to evade T cell responses. For example, viruses can inhibit MHC class I presentation by blocking peptide transport or degrading MHC molecules. Understanding these evasion strategies is essential for vaccine development and antiviral therapies.
From T cell antigen processing and presentation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate MHC class I presentation in T cells? | CRISPR knockout of gene X in primary T cells or Jurkat cells |
| What is the effect of a point mutation in TAP1 on peptide transport? | CRISPR point mutation knock-in in TAP1 locus |
| Can overexpression of cathepsin S enhance antigen presentation? | Lentiviral overexpression of CTSS in T cells |
| How does tagging MHC class II with GFP affect its trafficking? | CRISPR knock-in of GFP tag into HLA-DRA locus |
| Does Wnt5A signaling modulate antigen presentation in CD8 T cells? | Wnt5a knockout and overexpression in mouse T cells |
| What is the role of extracellular vesicle DNA in antigen presentation? | CRISPR knockout of DNA sensors in T cells; EV transfer assays |
How to Study the T cell antigen processing and presentation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC expression and peptide-MHC complexes | Quantifying antigen presentation in T cell populations |
| Immunopeptidomics | Peptide sequences bound to MHC molecules | Discovering novel antigens for vaccines |
| CRISPR screens | Genes regulating antigen presentation | Identifying therapeutic targets to boost immunity |
| Confocal microscopy | Intracellular trafficking of MHC and antigens | Visualizing presentation pathways |
| Western blot | Protein expression of antigen processing machinery | Validating knockout or overexpression efficiency |
| ELISPOT | Cytokine secretion by antigen-specific T cells | Assessing functional T cell activation |
| Tetramer staining | Antigen-specific T cell frequency | Monitoring immune responses to vaccines |
| RNA-seq | Transcriptional profiling of antigen presentation genes | Identifying regulatory networks |
Flow Cytometry and Immunophenotyping
Flow cytometry is widely used to measure surface expression of MHC molecules and antigen presentation markers on T cells. It allows quantification of peptide-MHC complexes using specific antibodies or tetramers. This method is essential for assessing the efficiency of antigen presentation in various experimental conditions.
Mass Spectrometry-Based Immunopeptidomics
Immunopeptidomics enables the identification of peptides presented by MHC molecules on the cell surface. This technique involves immunoaffinity purification of peptide-MHC complexes followed by mass spectrometry to sequence the bound peptides. It provides a comprehensive view of the antigenic repertoire and is valuable for vaccine target discovery.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR screens can identify genes that regulate antigen processing and presentation. By using reporter systems or MHC surface expression as readouts, researchers can uncover novel regulators and pathways. These screens are powerful for discovering therapeutic targets to enhance anti-tumor immunity.
Imaging and Live-Cell Analysis
Advanced imaging techniques, such as confocal microscopy and live-cell imaging, allow visualization of antigen processing and presentation in real time. Fluorescently tagged MHC molecules and antigens can track intracellular trafficking and surface presentation. These methods provide spatial and temporal insights into the presentation process.
How CRISPR Can Be Used to Study GO:0002457 T cell antigen processing and presentation
Knockout
CRISPR knockout is used to ablate genes involved in T cell antigen processing and presentation, such as B2M, TAP1, or CTSS, to study their essential roles. Knockout models help determine whether a gene is required for MHC surface expression, peptide loading, or T cell activation. These models are also valuable for identifying mechanisms of immune evasion in cancer.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific disease-associated or functional mutations into genes like TAP1 or HLA alleles. This approach enables precise dissection of how single amino acid changes affect peptide transport, MHC stability, or antigen presentation. Point mutation models are particularly useful for studying autoimmune risk alleles.
Knock-in
CRISPR knock-in can be used to tag endogenous MHC molecules or antigen processing proteins with fluorescent or epitope tags for tracking and purification. It also allows the insertion of reporter genes under the control of endogenous promoters to monitor antigen presentation in real time. Knock-in models facilitate the study of protein localization and dynamics.
Overexpression
CRISPR-mediated overexpression or lentiviral overexpression of genes such as CTSS or WNT5A can enhance antigen presentation and boost T cell responses. Overexpression models are used to test whether increasing the levels of a specific gene can overcome immune evasion or improve vaccine efficacy. These models are valuable for preclinical development of immunotherapies.
How EDITGENE Supports T cell antigen processing and presentation Research
Researchers studying T cell antigen processing and presentation-related genes often need to determine whether a candidate gene is causally involved in MHC expression, peptide loading, or T cell activation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for T cell antigen processing and presentation research.
Frequently Asked Questions About T cell antigen processing and presentation
What is GO:0002457?
GO:0002457 is the Gene Ontology term for T cell antigen processing and presentation, defined as the process in which a T cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.
What genes are involved in T cell antigen processing and presentation?
Key genes include HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, TAPBP, HLA-DRA, HLA-DRB1, CD74, CTSB, CTSL, CTSS, PSMB8, PSMB9, PSMB10, CD1D, and WNT5A.
Why is T cell antigen processing and presentation important in cancer?
It is critical for T cell recognition and killing of tumor cells; defects in this process allow tumors to evade immune detection and resist immunotherapy.
How is T cell antigen processing and presentation studied?
Common methods include flow cytometry, immunopeptidomics, CRISPR screens, imaging, and functional assays such as ELISPOT and tetramer staining.
What is the difference between T cell antigen processing and presentation and antigen presentation by dendritic cells?
While both involve MHC-mediated presentation, T cell antigen processing and presentation occurs within T cells themselves and can influence T cell-T cell interactions and thymic selection, whereas dendritic cells are specialized professional APCs.
Can T cells present lipid antigens?
Yes, T cells can present lipid antigens via CD1 molecules to specialized T cell subsets such as NKT cells.
What diseases are associated with defects in T cell antigen processing and presentation?
Defects are linked to cancer immune evasion, autoimmune diseases, immunodeficiencies, and increased susceptibility to infections.
How can CRISPR be used to study T cell antigen processing and presentation?
CRISPR knockout, point mutation knock-in, knock-in tagging, and overexpression models allow precise manipulation of genes involved in this process to study their functions and identify therapeutic targets.
What is the role of beta-2-microglobulin (B2M) in T cell antigen presentation?
B2M is the light chain of MHC class I; its loss leads to defective MHC class I presentation and is a common mechanism of immune evasion in cancer.
What are the therapeutic implications of targeting T cell antigen processing and presentation?
Enhancing antigen presentation can boost anti-tumor immunity and improve vaccine efficacy, while modulating it can help treat autoimmune diseases.
Conclusion
T cell antigen processing and presentation (GO:0002457) is a fundamental biological process that enables T cells to present antigens and shape immune responses. Its dysregulation is implicated in cancer, autoimmunity, and immunodeficiencies, making it a key area of research. Advances in CRISPR-based models and functional genomics are accelerating our understanding of this pathway and opening new avenues for therapeutic intervention.
References
- 1. Pishesha N et al.. 2022. A guide to antigen processing and presentation.. Nat Rev Immunol 22(12):751-764 PMID: 35418563
- 2. Jhunjhunwala S et al.. 2021. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.. Nat Rev Cancer 21(5):298-312 PMID: 33750922
- 3. Han Y et al.. 2026. Intratumoural vaccination via checkpoint degradation-coupled antigen presentation.. Nature 650(8102):736-747 PMID: 41501465
- 4. Hu M et al.. 2026. Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.. Cancer Cell 44(5):965-982.e12 PMID: 42066762
- 5. Mellman I et al.. 2010. Antigen processing and presentation.. Curr Opin Immunol 22(1):78-80 PMID: 20172702
- 6. Sarraf TR et al.. 2022. Wnt5A signaling supports antigen processing and CD8 T cell activation.. Front Immunol 13:960060 PMID: 36091060
- 7. Kondo K et al.. 2017. Antigen processing and presentation in the thymus: implications for T cell repertoire selection.. Curr Opin Immunol 46:53-57 PMID: 28477557
- 8. Huber F et al.. 2026. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development.. Nat Rev Immunol 26(1):23-34 PMID: 40781552
